Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Neoplasms 73%
3. Lung Neoplasms 60%
4. Small Cell Lung Carcinoma 59%
5. Survival 48%
6. Pemetrexed 37%
7. Drug Therapy 32%
8. Therapeutics 29%
9. Lung 28%
10. pazopanib 28%
11. Carcinoid Tumor 27%
12. Carboplatin 25%
13. Malignant Mesothelioma 24%
14. Maximum Tolerated Dose 23%
15. Mesothelioma 19%
16. Genes 19%
17. Sorafenib 18%
18. Confidence Intervals 18%
19. ErbB Receptors 18%
20. Protein-Tyrosine Kinases 18%
21. Progression-Free Survival 18%
22. Anaplastic Thyroid Carcinoma 17%
23. Pharmacokinetics 16%
24. Methylation 16%
25. Cisplatin 16%
26. Topotecan 15%
27. Erlotinib Hydrochloride 15%
28. 10-propargyl-10-deazaaminopterin 14%
29. Biomarkers 13%
30. vatalanib 13%
31. Cell Line 13%
32. Carcinogenesis 13%
33. Anaplastic Lymphoma Kinase 12%
34. Adenoid Cystic Carcinoma 12%
35. Mutation 12%
36. Clinical Trials 12%
37. Smokers 11%
38. Adenocarcinoma 11%
39. Paclitaxel 11%
40. Heterografts 11%
41. Pancreatic Neoplasms 11%
42. Fatigue 10%
43. Safety 10%
44. Neuroendocrine Tumors 10%
45. Bortezomib 10%
46. Platinum 10%
47. Docetaxel 10%
48. Decitabine 10%
49. Methyltransferases 10%
50. DNA 10%